Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$592 Mln
P/E Ratio
--
P/B Ratio
3.82
Industry P/E
81.98
Debt to Equity
1.59
ROE
-0.89 %
ROCE
--
Div. Yield
0.57 %
Book Value
--
EPS
-46.25
CFO
$234.05 Mln
EBITDA
$179.34 Mln
Net Profit
$52.88 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mesa Laboratories (MLAB)
| -13.70 | -9.06 | -21.44 | 11.28 | -21.24 | -12.58 | 3.32 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Mesa Laboratories (MLAB)
| 25.63 | -36.97 | -49.34 | 14.46 | 14.93 | 19.68 | 67.18 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.65 | 10,289.47 | 14.38 | 12.69 | |
| 72.28 | 9,544.04 | 92.52 | 2.52 | |
| 158.95 | 8,064.21 | -- | -25.23 | |
| 278.44 | 10,728.90 | 773.26 | 1.2 |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control... segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Address: 12100 West Sixth Avenue, Lakewood, CO, United States, 80228 Read more
CEO, President & Director
Mr. Gary M. Owens
CEO, President & Director
Mr. Gary M. Owens
Headquarters
Lakewood, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mesa Laboratories Inc (MLAB) stood at $ 593 Mln as on 31-Dec-24
The share price of Mesa Laboratories Inc (MLAB) is $113.80 (NASDAQ) as of 23-Apr-2025 14:37 EDT. Mesa Laboratories Inc (MLAB) has given a return of -21.24% in the last 3 years.
Mesa Laboratories Inc (MLAB) has a market capitalisation of $ 592 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Mesa Laboratories Inc (MLAB) is 3.82 times as on 22-Apr-2025, a 17% premium to its peers’ median range of 3.26 times.
Since, TTM earnings of Mesa Laboratories Inc (MLAB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mesa Laboratories Inc (MLAB) and enter the required number of quantities and click on buy to purchase the shares of Mesa Laboratories Inc (MLAB).
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Address: 12100 West Sixth Avenue, Lakewood, CO, United States, 80228
The CEO & director of Mr. Gary M. Owens. is Mesa Laboratories Inc (MLAB), and CFO & Sr. VP is Mr. Gary M. Owens.
There is no promoter pledging in Mesa Laboratories Inc (MLAB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Mesa Laboratories Inc. (MLAB) | Ratios |
|---|---|
|
Return on equity(%)
|
-163.07
|
|
Operating margin(%)
|
-109.2
|
|
Net Margin(%)
|
-104.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mesa Laboratories Inc (MLAB) was $0 Mln.
$0.76
(
